Abnormal cervical smears in the unchanged uterine cervix: difficulties in the screening, diagnosis, and treatment of cervical intraepithelial neoplasias and microinvasive cancer
https://doi.org/10.17650/1994-4098-2011-0-3-74-78
Abstract
The author analyzes an algorithm for identifying and treating w omen with cervical intraepithelial neoplasias (CIN) and microinv asive cancer of the cervix uteri in cases of the hidden area of transformation and in the absence of visible cervical changes. There are excep- tional difficulties of making the diagnosis of epithelial damages due to the incomplete reproducibility of cytological abnormal ities and the low informative value of a histological study of scrapes from the cervical canal. To avoid hypodiagnosis, it is justifiable to prefer human papillomavirus testing (Hybrid Capture 2 (HC2)) to repeat smears for the choice of a management tactic. Conization is recommend ed as a diagnostic and/or therapeutic procedure when the viral load is high in over 35-year-old patients with abnormal smears anda hidden transformation area.
About the Author
L. I. Korolenkova
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
References
1. European guidelines for quality assurance in cervical cancer screening. European Communities, 2008; p. 291.
2. Nieh S.F., Chen T.Y., Chu H.C. et al. Expression of p16INK4a in Papanicolaou smears containing atypical squamous cells of undetermined significance from the uterine cervix. Gynecol Oncol 2003;91:201–8.
3. Kitchener H.C., Almonte M., Gilham C. et al. ARTISTIC: a randomised trial of human papillomavirus (HPV) testing in primary cervical screening. Health Technol Assess 2009;13(51):1−150.
4. Cuzick J., Clavel C., Petry K.U. et al. Overview of European and North American Studies on HPV-testing and primary cervical cancer screening. Int J Cancer 2006;119 (5):1095−101.
5. Bentley E., Cotton S.C., Cruickshank M.E. et al. Refining the management of low-grade cervical abnormalities in the UK National Health Service and defining the potential for human papillomavirus testing: a commentary on emerging evidence. Trial of Management of Borderline and Other Low-Grade Abnormal Smears (TOMBOLA) Group. J Low Genit Tract Dis 2006;10(1):26−38.
6. Rijkaart D.C., Coupe V.M., van Kemenade F.J. et al. Comparison of Hybrid capture 2 testing at different thresholds with cytology as primary cervical screening test. Br J Cancer 2010;103(7):939−46.
7. Jordan J., Martin-Hirsch P., Arbyn M. et al. European guidelines for clinical management of abnormal cervical cytology. Cytopathology 2009; 20 (1):5−16.
8. Sellors J.W., Sankaranarayanan R. Colposcopy and treatment of cervical intraepithelial neoplasia: a beginners’ manual. International Agency for Research on Cancer: Lyon, 2003.
9. Monsonego J., Pintos J., Semaille C. et al. Human papillomavirus testing improves the accuracy of colposcopy in detection of cervical intraepithelial neoplasia. Int J Gynecol Cancer 2006; 16(2):591−8.
10. Zhao F.H., Hu S.Y., Wang S.M. et al. Association between high-risk human papillomavirus DNA load and different histological grades of cervical neoplasm. Zhonghua Yu Fang Yi Xue Za Zhi 2009;43(7:565−70.
11. McCredie M.R., Sharples K.J., Paul C. et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol 2008;9:425−34.
Review
For citations:
Korolenkova L.I. Abnormal cervical smears in the unchanged uterine cervix: difficulties in the screening, diagnosis, and treatment of cervical intraepithelial neoplasias and microinvasive cancer. Tumors of female reproductive system. 2011;(3):74-78. (In Russ.) https://doi.org/10.17650/1994-4098-2011-0-3-74-78
Views:
734
Email this article 